Quantcast
Channel: genocea – Herpes Survival Kit
Browsing latest articles
Browse All 11 View Live

Genocea Reports Third Quarter 2015 Financial Results

On October 7, 2015, Genocea reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for...

View Article



Genocea Presents Positive Findings from ATLASTM Immuno-Oncology Research …

Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and...

View Article

Genocea to Present at the Piper Jaffray 27th Annual Healthcare Conference

Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and...

View Article

Genocea to Present at the Stifel 2015 Healthcare Conference

Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and...

View Article

What I Like About Genocea

The therapeutic vaccine candidate is currently in Phase II for the treatment of genital herpes infections. Data from Phase 1/2a trial so far has been encouraging. Most recent data from the Phase II...

View Article


Genocea to Present at 2016 BIO CEO & Investor Conference

Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and...

View Article

Genocea to Host Fourth Quarter and Year End 2015 Financial Results Conference …

Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and...

View Article

Genocea Reports Fourth Quarter and Year-End 2015 Financial Results

In October, we demonstrated significant and durable Phase 2 efficacy for GEN-003, potentially positioning it to become the cornerstone treatment for the millions of people who suffer from genital...

View Article


Genocea Doses Patients in Phase IIb Study on GEN-003

According to the World Health Organization (WHO), more than 400 million people across the world are affected by genital herpes. As treatment options for genital herpes are limited, Genocea estimates...

View Article


Genocea Congratulates Dr. George Siber, 2016 Albert B. Sabin Gold Medal Award …

Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (development...

View Article

Genocea to Host First Quarter 2016 Financial Results Conference Call & Webcast …

Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (currently...

View Article
Browsing latest articles
Browse All 11 View Live




Latest Images